-9.7 (-0.78%)
  • Advice
  • Hold
As on 11 December, 2023 | 18:44 BSE: 500257 NSE: LUPINISIN: INE326A01037

Lupin Performance

Day Range

  • Low 1,224.05
  • High 1,247.20
₹ 1,229.65

52 Week Range

  • Low 628.00
  • High 1,308.95
₹ 1,229.65
  • Open Price1,239.50
  • Previous Close1,239.35
  • Volume621598

Start SIP in Lupin

Start SIP

Lupin Share Price

  • Over 1 Month 4.19%
  • Over 3 Month 9.16%
  • Over 6 Month 52.49%
  • Over 1 Year 63.63%

Lupin Key Statistics

P/E Ratio 42.1
PEG Ratio 0
Market Cap Cr 55,985
Price to Book Ratio 4.5
Dividend 0.3
Relative Strength Index 52.48
Money Flow Index 67.72
MACD Signal 21.79
Average True Range 27.98

Lupin Investment Rating

  • Master Rating:
  • Lupin (Nse) has an operating revenue of Rs. 18,604.92 Cr. on a trailing 12-month basis. An annual revenue growth of 1% is not great, Pre-tax margin of 4% needs improvement, ROE of 3% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 32% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 74 which is a FAIR score but needs to improve its earnings, a RS Rating of 75 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 68 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of A is the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock definitely has some strength, you may want to examine it in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Lupin Financials
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 3,5603,4962,7452,8612,8292,6842,504
Operating Expenses Qtr Cr 2,8242,7912,5742,6462,5152,4442,354
Operating Profit Qtr Cr 835705262215314289501
Depreciation Qtr Cr 149140146134138130131
Interest Qtr Cr 15162931182025
Tax Qtr Cr 14710023272428397
Net Profit Qtr Cr 54947711940149117-36
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 11,35011,922
Operating Expenses Annual Cr 10,17611,496
Operating Profit Annual in Cr 1,083276
Depreciation Cr 548514
Interest Annual Cr 9873
Tax Annual Cr 10227
Net Profit Annual Cr 425-189
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 1,794151
Cash from Investing Activity Annual Cr -1,269-372
Cash from Financing Annual Activity Cr -498102
Net Cash Flow Annual Cr 27-118
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 18,41218,150
Fixed Assets Annual Cr 4,9494,638
Total Non Current Assets Annual Cr 15,11313,876
Total Current Assets Annual Cr 7,5718,438
Total Assets Annual Cr 22,68422,313
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 405399
ROE Annual % 2-1
ROCE Annual % 30
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 104
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 4,9394,8144,3304,3224,1463,6043,865
Operating Expenses Qtr Cr 4,1213,9583,8523,7903,6933,5123,615
Operating Profit Qtr Cr 918856578533453232268
Depreciation Qtr Cr 248235264220203193327
Interest Qtr Cr 81869384554341
Tax Qtr Cr 13410516887589427
Net Profit Qtr Cr 489452236153130-89-518
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 16,71516,547
Operating Expenses Annual Cr 14,84416,118
Operating Profit Annual in Cr 1,798287
Depreciation Cr 8811,659
Interest Annual Cr 274143
Tax Annual Cr 269137
Net Profit Annual Cr 430-1,528
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 1,897367
Cash from Investing Activity Annual Cr -1,2871,292
Cash from Financing Annual Activity Cr -337-1,572
Net Cash Flow Annual Cr 27387
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 12,46512,153
Fixed Assets Annual Cr 7,3746,404
Total Non Current Assets Annual Cr 10,5059,364
Total Current Assets Annual Cr 12,45112,458
Total Assets Annual Cr 22,95621,821
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 276269
ROE Annual % 3-13
ROCE Annual % 7-9
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 113

Lupin Technicals


Current Price
-9.7 (-0.78%)
  • Bullish Moving Average
  • ___
  • 10
  • Bearish Moving Average
  • ___
  • 6
  • 20 Day
  • ₹1,230.40
  • 50 Day
  • ₹1,190.69
  • 100 Day
  • ₹1,119.08
  • 200 Day
  • ₹1,008.04
  • 20 Day
  • ₹1,227.26
  • 50 Day
  • ₹1,191.97
  • 100 Day
  • ₹1,131.07
  • 200 Day
  • ₹941.17

Lupin Resistance and Support

First Resistance 1,243.22
Second Resistance 1,256.78
Third Resistance 1,266.37
RSI 52.48
MFI 67.72
MACD Single Line 21.79
MACD 18.87
First Resistance 1,220.07
Second Resistance 1,210.48
Third Resistance 1,196.92

Lupin Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 684,205 35,619,712 52.06
Week 1,163,423 72,015,859 61.9
1 Month 1,365,005 69,533,378 50.94
6 Month 1,278,660 51,772,950 40.49

Lupin Result Highlights

Lupin Synopsis

NSE-Medical-Generic Drugs

Lupin Ltd. is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 11258.83 Cr. and Equity Capital is Rs. 91.00 Cr. for the Year ended 31/03/2023. Lupin Ltd. is a Public Limited Listed company incorporated on 01/03/1983 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24100MH1983PLC029442 and registration number is 029442.
Market Cap 55,982
Sales 12,852
Shares in Float 24.13
No of funds 627
Yield 0.32
Book Value 3.06
U/D Vol ratio 1.2
LTDebt / Equity
Alpha 0.18
Beta 0.57


Owner NameSep-23Jun-23Mar-23Dec-22
Promoters 47.06%47.07%47.08%47.1%
Mutual Funds 16.71%17%16.96%16.47%
Insurance Companies 12.26%11.84%11.73%11.39%
Foreign Portfolio Investors 14.99%13.93%13.32%13.98%
Financial Institutions/ Banks 0.14%0.14%0.14%0.14%
Individual Investors 6.24%7.06%7.86%8.06%
Others 2.6%2.96%2.91%2.86%

Lupin Management

Name Designation
Mrs. Manju D Gupta Chairman
Mr. Nilesh D Gupta Managing Director
Mr. Ramesh Swaminathan Executive Director & Global CFO
Ms. Vinita Gupta Director & CEO
Mr. Jean-Luc Belingard Independent Director
Mr. K B S Anand Independent Director
Dr. Punita Kumar-Sinha Independent Director
Mr. Mark D McDade Independent Director

Lupin Forecast

Price Estimates


Other Analyst Rating

Lupin Corporate Action

Date Purpose Remarks
2023-11-08 Quarterly Results
2023-08-03 Quarterly Results
2023-05-09 Audited Results & Final Dividend
2023-02-09 Quarterly Results
2022-11-09 Quarterly Results
Date Purpose Remarks
2023-07-14 FINAL Rs.4.00 per share (200%)Final Dividend
2022-07-15 FINAL Rs.4.00 per share(200%)Final Dividend
2021-07-28 FINAL Rs.6.50 per share(325%)Final Dividend

Lupin MF Shareholding

Name Amount(cr)
HDFC Balanced Advantage Fund Growth 63,981
ICICI Prudential Balanced Advantage Fund Growth 49,871
HDFC Flexi Cap Fund Growth 42,271
ICICI Prudential Bluechip Fund Growth 41,269
ICICI Prudential Value Discovery Fund Growth 32,494

About Lupin

Dr Desh Bandhu Gupta founded in 1968 in Mumbai, Lupin is one of the top pharmaceutical manufacturers. It has 15 manufacturing facilities, 6 API facilities, 7 research facilities and more than 23 global offices. 

Lupin ranks 6th by sales in India. It ranks #2 in respiratory and #3 in cardiac and anti-diabetes segments. While the market growth in the chronic disease portfolio has been 11% in the last five years, Lupin has been growing at 14% YoY.
Over the last 4 years, it has invested over $1bn in R&D in areas of biosimilars, complex generics, long-acting complex injectables, inhalation and speciality portfolio. 

Business Verticals

1. Global Formulations
2. Active Pharmaceuticals Ingredients (API)
3. Biotech
4. Specialty Business
5. Over The Counter (OTC)
6. Biosimilars
7. Generic drugs

Company History

Lupin commenced operations in 1968 on Gudi Padwa as a vitamins manufacturer. It is named after the Lupin flower, which can tolerate infertile soils and poor climatic conditions. Its first major order was iron and folic acid tablets for mother and child healthcare programmes backed by the Government of India.

Today, it develops branded and generic formulations, APIs, and biotechnology products and sells across 100 markets, including the US, Japan, and Mexico. Lupin is one of the world's largest manufacturers of TB drugs. The company has a significant market share across multiple therapy areas such as Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System, Gastro-Intestinal, Anti-Infective, and Non-Steroidal Anti-Inflammatory Drugs. 


1968 - Dr Desh Bandhu Gupta started Lupin.

1972 - Lupin Laboratories Pvt. Ltd. was incorporated.

1979 - They commissioned the first formulation plant and R&D Centre at Aurangabad.

1981 - They started the production of Ethambutol.

1987 - Cephalexin plant at Mandideep and 7 ADCA plants at Ankleshwar went on stream.

1988 - Commenced Lupin Human Welfare and Research Foundation (LHWRF).

1989 - Started Lupin Chemicals (Thailand) Ltd. Received U.S. FDA approvals for the Ankleshwar and Mandideep plants.

1991 - Initiated the production of injectable Cephalosporin at Mandideep.

1992 - Commenced a sterile fermentation plant for injectable Cephalosporins at Mandideep.

1993 - Lupin Laboratories Ltd. and Lupin Chemicals Ltd. floated their IPOs.

1997 - Three facilities received U.S. FDA approvals.

2000 - Another plant received US FDA approval.

2001 - Lupin Laboratories Ltd. amalgamated with Lupin Chemicals Ltd. to form Lupin Ltd. and established the Lupin Research Park in Pune. Lupin became the only Asian pharmaceutical company to receive U.S. FDA approvals for its sterile Cephalosporin facility.

2002 - ORG-Marg rated Rablet as the 2nd best launch of 2002-03; patent filings exceed 100.

2003 - Received WHO approval for the formulation plant at Aurangabad. Lupin Pharmaceuticals Inc. USA is formed.

2004 - Started U.S. brands’ business with the launch of Suprax.

2005 - Commenced its generics business in the U.S. Implemented ESOP.

2006 - Announced the issue of FCCBs, with a listing on the Singapore Stock Exchange.

2007 - Acquired Kyowa Pharmaceuticals of Japan; and Rubamin Laboratories of India.

2008 - Acquired Hormosan Pharma GmbH, Germany. Also acquired stakes in Generic. Health Pty Ltd., Australia and Pharma Dynamics, South Africa.

2009 - Acquired majority stake in Multi-Care Pharmaceuticals Inc., Philippines.

2010 - Lupin ranked the 5th largest generic player in the U.S.

2011 - Began commercial production at the new oral solid dosage facility at Pithampur; acquired I’rom Pharmaceuticals, Japan and of worldwide rights for the Goanna Brand.

2012 - Lupin enters Nifty 50.

2014 - Acquired Nanomi BV of the Netherlands and Laboratorios Grin S.A. De C.V., Mexico.

2015 - Acquired Pharma Dynamics, South Africa, Medquimica Industria, Brazil; Specialty product portfolio of Temmler Pharma GMBH & Co., Germany.

2016 - Acquired Gavis Pharma, U.S; launched a new plant at Tottori, Japan.

2017 - Launched Softovac in the OTC segment; acquired Symbiomix Therapeutics, U.S.

2019 - Divestment of Kyowa Pharmaceutical Industry Co. Ltd., in Osaka.

2020 - Launched Etanercept Biosimilar in EU and gProAir, a key inhalation product.

Lupin FAQs

What is Share Price of Lupin ?

Lupin share price is ₹1,229 As on 11 December, 2023 | 18:30

What is the Market Cap of Lupin ?

The Market Cap of Lupin is ₹55984.6 Cr As on 11 December, 2023 | 18:30

What is the P/E ratio of Lupin ?

The P/E ratio of Lupin is 42.1 As on 11 December, 2023 | 18:30

What is the PB ratio of Lupin ?

The PB ratio of Lupin is 4.5 As on 11 December, 2023 | 18:30

What were the company's reported sales and net income in 2022?

For the year ending March 2022, Lupin reported a consolidated sales figure of INR 16,405 crores and a net loss of INR 1,528 crores. Its standalone sales and net loss for the same period stood at INR 11,772 crores and 189 crores respectively.

What is the future of Lupin Limited's shares?

Lupin’s future looks slightly bleak. The company has shown a negative net profit growth rate of 2.18% and revenue growth of 3.10% for the past 3 years. However, the company is virtually debt-free.

How to buy Lupin’s shares?

You can easily buy and sell the company's shares by creating a Demat account with 5Paisa.